type 2 diabetes mellitus is an ever increasing complex endocrine and metabolic disorder while its management has still remains as a complex and challenging issue and the need for novel approaches to treat hyperglycemia simply cannot be ignored. SGLT 2 inhibitors are also reliable new class of antidiabetic drugs such as Dapagliflozin and Canagliflozin are currently approved in the US, Europe and Japan. They cause both weight loss and glycemic control effectively with a low risk of hypoglycemia.However, it is still not certain if SGLT2 inhibitors can improve the clinical effect of diabetes, like micro- or macrovascular late complications.